← Leaderboards
David Wininger
Ohio State University
$45,298
Attributed
$45,298
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $24.5K · FY2005–08$25K$18.8K$12.5K$6.3K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$45,298 · 5
By mechanism
M01$45,298 · 5
Top collaborators
No co-investigators on record.
Most similar at Ohio State University
Same institution · by research overlap
- Philip A. Hart$2,976,713
- Steven K Clinton$5,749,067
- Terry A Lennie$4,001,193
- Francis G Gress$95,263
- Steven J Schwartz$1,373,419
Others in their field
Top investigators on “Zidovudine”
- Willard Cates · Family Health International$66,963,584
- Jay B Jackson · Johns Hopkins University$17,529,470
- Stephen J Durako · Westat, Inc.$15,048,684
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$11,770,144
- Marc J Lallemant · Harvard University (Sch Of Public Hlth)$11,626,990
- Laura A Guay · Johns Hopkins University$11,000,941
Research focus
ZidovudineHuman SubjectHiv InfectionsAids TherapyHuman Therapy EvaluationClinical ResearchCombination ChemotherapyDelavirdineDrug Screening /EvaluationClinical TrialsDrug Administration RoutesAntiretroviral TherapyIndinavirDouble-Blind MethodFood SupplementsButtocksFatty Acid Glycerol EstersFaceEuropeFundingGrantHiv-1Computer Retrieval Of Information On Scientific Projects DatabaseAztec Brand Of Zidovudine
Grant awards (7)
CLINICAL TRIAL: TRIAL OF URIDINE SUPPLEMENTATION IN HIV LIPOATROPHY$24,483
M01 · FY2008 · RR · contact PI
TRIAL OF URIDINE SUPPLEMENTATION IN HIV LIPOATROPHY$1,943
M01 · FY2007 · RR · contact PI
A5082: A STUDY OF METFORMIN AND ROSIGLITAZONE IN HIV-INFECTED PATIENTS$5,380
M01 · FY2005 · RR
A Study Of Metformin &Rosiglitazone in HIV-Infected Pts$13,492
M01 · FY2004 · RR
PROTEASE INHIBITOR/REVERSE TRANSCRIPTASE INHIBITOR$0
M01 · FY2000 · RR
PHASE II STUDY OF INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN 2 BY INTRAVENOUS$0
M01 · FY2000 · RR
PHASE II STUDY OF INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN 2 BY INTRAVENOUS$0
M01 · FY2000 · RR